🚀 VC round data is live in beta, check it out!
Julphar Valuation Multiples
Discover revenue and EBITDA valuation multiples for Julphar and similar public comparables like Cybin, Surrozen, Hansa Biopharma, DiaMedica and more.
Julphar Overview
About Julphar
Gulf Pharmaceutical Industries PSC is in the business of manufacturing and selling medicines, drugs, and various other types of pharmaceutical and medical compounds in addition to cosmetic compounds. The company operates in four segments: Manufacturing, Planet, Investments, and others. The majority of its revenue is generated from the planet segment. The geographical segments are UAE, Other GCC countries, and Other countries.
Founded
1980
HQ
Employees
2.3K
Website
Sectors
Financials (LTM)
EV
$329M
Julphar Financials
Julphar reported last 12-month revenue of $292M and EBITDA of $29M.
In the same LTM period, Julphar generated $29M in EBITDA and $11M in net income.
Revenue (LTM)
Julphar P&L
In the most recent fiscal year, Julphar reported revenue of $293M and EBITDA of $36M.
Julphar expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $292M | XXX | $293M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $119M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 41% | XXX | XXX | XXX |
| EBITDA | $29M | XXX | $36M | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 12% | XXX | XXX | XXX |
| EBIT Margin | 4% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | $11M | XXX | $47M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 16% | XXX | XXX | XXX |
| Net Debt | — | — | $9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Julphar Stock Performance
Julphar has current market cap of $327M, and enterprise value of $329M.
Market Cap Evolution
Julphar's stock price is $0.28.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $329M | $327M | -0.1% | XXX | XXX | XXX | $0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialJulphar Valuation Multiples
Julphar trades at 1.1x EV/Revenue multiple, and 11.4x EV/EBITDA.
EV / Revenue (LTM)
Julphar Financial Valuation Multiples
As of April 12, 2026, Julphar has market cap of $327M and EV of $329M.
Equity research analysts estimate Julphar's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Julphar has a P/E ratio of 29.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $327M | XXX | $327M | XXX | XXX | XXX |
| EV (current) | $329M | XXX | $329M | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | 11.4x | XXX | 9.0x | XXX | XXX | XXX |
| EV/EBIT | 25.2x | XXX | 19.0x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 2.8x | XXX | XXX | XXX |
| P/E | 29.0x | XXX | 7.0x | XXX | XXX | XXX |
| EV/FCF | 30.1x | XXX | 16.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Julphar Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Julphar Margins & Growth Rates
Julphar's revenue in the last 12 month grew by 2%.
Julphar's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Julphar's rule of 40 is 8% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Julphar's rule of X is 7% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Julphar Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | (1%) | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | (0%) | XXX | (30%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 8% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 7% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 24% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 9% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 35% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Julphar Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cybin | XXX | XXX | XXX | XXX | XXX | XXX |
| Surrozen | XXX | XXX | XXX | XXX | XXX | XXX |
| Hansa Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| DiaMedica | XXX | XXX | XXX | XXX | XXX | XXX |
| Clinuvel Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Julphar M&A Activity
Julphar acquired XXX companies to date.
Last acquisition by Julphar was on XXXXXXXX, XXXXX. Julphar acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Julphar
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialJulphar Investment Activity
Julphar invested in XXX companies to date.
Julphar made its latest investment on XXXXXXXX, XXXXX. Julphar invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Julphar
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Julphar
| When was Julphar founded? | Julphar was founded in 1980. |
| Where is Julphar headquartered? | Julphar is headquartered in United Arab Emirates. |
| How many employees does Julphar have? | As of today, Julphar has over 2K employees. |
| Is Julphar publicly listed? | Yes, Julphar is a public company listed on Abu Dhabi Securities Exchange. |
| What is the stock symbol of Julphar? | Julphar trades under JULPHAR ticker. |
| When did Julphar go public? | Julphar went public in 2002. |
| Who are competitors of Julphar? | Julphar main competitors are Cybin, Surrozen, Hansa Biopharma, DiaMedica. |
| What is the current market cap of Julphar? | Julphar's current market cap is $327M. |
| What is the current revenue of Julphar? | Julphar's last 12 months revenue is $292M. |
| What is the current revenue growth of Julphar? | Julphar revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Julphar? | Current revenue multiple of Julphar is 1.1x. |
| Is Julphar profitable? | Yes, Julphar is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Julphar? | Julphar's last 12 months EBITDA is $29M. |
| What is Julphar's EBITDA margin? | Julphar's last 12 months EBITDA margin is 10%. |
| What is the current EV/EBITDA multiple of Julphar? | Current EBITDA multiple of Julphar is 11.4x. |
| What is the current FCF of Julphar? | Julphar's last 12 months FCF is $11M. |
| What is Julphar's FCF margin? | Julphar's last 12 months FCF margin is 4%. |
| What is the current EV/FCF multiple of Julphar? | Current FCF multiple of Julphar is 30.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.